Alpa Laboratories
- Market cap
- ₹ 103 Cr.
- P/E
- 26.9x
- P/B
- 0.58x
- 52-week range
- 46.1 – 93.85
- ROE
- 8%
- ROCE
- 9%
- Dividend yield
- 0%
- Debt / equity
- 0.01
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Alpa Laboratories Limited is an India-based global pharmaceutical company engaged in manufacturing and selling finished pharmaceutical dosage forms. Its product range includes a variety of ethical, generic, and over the counter (OTC) drugs in various finished dosage forms for both human and veterinary use. Its human use products include capsules, such as Ampicillin Capsule IP/BP, Amoxycillin Trihydrate Capsule IP/BP, Cloxacillin Capsules IP/BP and Piroxicam Capsules IP BP; creams, gels and ointments, which include Lidocaine Hydrochloride Jelly IP/USP, Nitrofurazone Cream USP, Miconazole Cream IP/BP and Clobetasole Ointment/Cream BP; ear and eye drops, such as Benzylpenicillin Inj. IP/BP and Benzathine Penicillin Inj. IP/BP, and tablets, such as Ciprofloxacin Tablet IP / BP, Paracetamol Tablet IP/BP and Tinidazole Tablets IP/BP. Its veterinary products include boluses, such as Alpamin Bolus, Melovin-P Bolus and Alpazole Bolus, and injections, such as Atropine Inj. B.Vet.C and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Alpa Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)26.9 against a typical 34.3: cheaper than most peers (1st = cheapest).88th of 220
- Sales growth+25.2% against a typical +15.6% from a year earlier.67th of 197
- Profit growth−91.7% against a typical +18.9% from a year earlier.146th of 160
- Share price, 3 months−23% against a typical −0.5%.189th of 200
- Size₹ 103.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).147th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil B/Issuer Not Cooperating | Stable | 29 Aug 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 29 Aug 2025 | Rating action | Crisil B/Issuer Not Cooperating | — | CRISIL | ₹ 15 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 28 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 27 | 24 | 21 | 25 | 26 | 40 | 19 | 26 | 29 | 31 | 24 |
| Expenses | 29 | 25 | 20 | 21 | 22 | 25 | 40 | 19 | 29 | 28 | 28 | 28 |
| Operating Profit | 3 | 2 | 4 | 1 | 3 | 1 | 0 | 0 | −2 | 2 | 4 | −4 |
| OPM % | 10.3% | 8.9% | 14.9% | 2.5% | 13.3% | 2.8% | 0.5% | 2.3% | −8.6% | 5.2% | 11.5% | −16.6% |
| Other Income | 3 | 4 | 4 | 5 | 7 | 9 | 2 | 12 | 3 | 1 | −0 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Profit before tax | 6 | 5 | 7 | 5 | 10 | 9 | 2 | 12 | 0 | 2 | 3 | 1 |
| Tax % | 0% | 14.9% | 46.7% | 0% | 20.3% | 0% | 201.9% | 0% | 0% | 9.2% | 55.1% | 0% |
| Net Profit | 6 | 5 | 4 | 5 | 8 | 9 | −2 | 12 | 0 | 2 | 1 | 1 |
| EPS in Rs | 2.75 | 2.14 | 1.69 | 2.42 | 3.65 | 4.23 | −1.01 | 5.59 | 0.05 | 0.76 | 0.66 | 0.47 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- 4%
- TTM
- 0%
- 10 Years
- 8%
- 5 Years
- 24%
- 3 Years
- 6%
- TTM
- −85%
- 10 Years
- 6%
- 5 Years
- 3%
- 3 Years
- −4%
- TTM
- —
- 10 Years
- 7%
- 5 Years
- 10%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Alpa Laboratories | ₹ 52.25 | ₹ 103 Cr. | 26.9x | 0.6x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Purushottam R. Patel
- Chairman of the Board
- Jayesh P. Patel
- Chief Executive Officer
- Bakulesh C. Shah
- Chief Financial Officer
- Yashoda Patidar
- Compliance Officer, Company Secretary
- Paresh M. Chawla
- Managing Director, Director
- Mahendra Singh Chawla
- Whole-Time Director
- Pravin C. Shah
- Whole Time Director
- Shitul Shah
- Additional Director
Prices are delayed and for information only. Nothing on this page is investment advice.